The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer

Abstract This study examined the health‐related quality of life (HRQoL) of patients with advanced non‐small cell lung cancer (NSCLC) receiving tislelizumab versus docetaxel in the open‐label, multicenter, Phase 3 trial called RATIONALE‐303 (NCT03358875). HRQoL was assessed with the EORTC QLQ‐C30, EO...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Dingzhi Huang, Caicun Zhou, Gisoo Barnes, Yiyuan Ma, Songzi Li, Lin Zhan, Boxiong Tang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2023-08-01
Serie:	Cancer Medicine
Soggetti:	docetaxel health‐related quality of life non‐small cell lung cancer patient‐reported outcomes programmed cell death protein‐1 inhibitor
Accesso online:	https://doi.org/10.1002/cam4.6361
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!